Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY) Amid GLP-1 Pricing Uncertainty

Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $925.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented, "n a White House / FDA–joint media conference on this afternoon, the administration unveiled the first nine drugs selected to receive the new Commissioner’s National Priority Vouchers (CNPV) – and notably LLY’s orforglipron was not included. Given recent unrelenting speculation of a potential CNPV for orforglipron and some overly optimistic hopes for approval by YE25, the pressure on LLY shares after-hours is unsurprising. Notably, however, this comes against the backdrop of vague and at times contradictory GLP-1 pricing commentary (presumably referring to ongoing semaglutide IRA negotiations reaching $150/mo or lower). To be clear, the administration noted these negotiations are not yet finalized. Nevertheless, we see the pricing dynamic weighing more on LLY shares (given that investors had anchored expectations around the mid-$200s for IRA-negotiated semaglutide) than the CNPV list."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $819.38 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Full Circle Lithium closes $5.14M private placement